ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-12-05: Form 8-K; Period of report 2016-12-05; Description 8.01 Other Events; Details 8.01.
- 2016-11-07: Form 8-K; Period of report 2016-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-11-03: Form 8-K; Period of report 2016-10-31; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2016-09-27: Form 8-K; Period of report 2016-09-27; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-12-05 | 8-K | 2016-12-05 | 8.01 Other Events | 8.01 On December 5, 2016, Zogenix, Inc. (the “Company”) announced new data demonstrating effectiveness and cardiovascular-related safety for patients treated with ZX008 (low-dose fenfluramine) as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS), and continued effectiveness and safety for the on-going open-label patients with Dravet syndrome. | d299998d8k.htm |
| 2016-11-07 | 8-K | 2016-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2016, Zogenix, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2016. | a8-k9x30x16er.htm |
| 2016-11-03 | 8-K | 2016-10-31 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d83838d8k.htm |
| 2016-09-27 | 8-K | 2016-09-27 | 7.01 Regulation FD Disclosure | 7.01 Beginning on September 27, 2016, representatives of Zogenix, Inc. (“Zogenix”) will be attending meetings with investors, analysts and other parties in connection with the Ladenberg Thalmann 2016 Healthcare Conference in New York, NY. | d267467d8k.htm |
| 2016-08-26 | 8-K | 2016-08-23 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d242763d8k.htm |
| 2016-08-09 | 8-K | 2016-08-09 | 2.02 Results of Operations and Financial Condition | 2.02 On August 9, 2016, Zogenix, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2016. | a8-k6x30x16er.htm |
| 2016-07-13 | 8-K | 2016-07-13 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Zogenix, Inc. (the “Company”) held its annual meeting of stockholders on July 13, 2016. | d223651d8k.htm |
| 2016-07-11 | 8-K | 2016-07-08 | 8.01 Other Events | 8.01 On July 8, 2016, Zogenix, Inc. (the “Company”) determined to no longer seek stockholder approval of the one-time option exchange program (the “Option Exchange”) contemplated by the Company’s Schedule 14A filed with the Securities Exchange Commission on June 3, 2016. | d124530d8k.htm |
| 2016-06-21 | 8-K | 2016-06-17 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference in this Item 2.03. | d212601d8k.htm |
| 2016-06-07 | 8-K | 2016-06-07 | 8.01 Other Events | 8.01 On June 7, 2016, Zogenix, Inc. (the “Company”) announced the initiation of its second Phase 3 clinical trial, a multi-national study (“Study 1502”), for the Company’s lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. | d176694d8k.htm |
| 2016-05-10 | 8-K | 2016-05-10 | 2.02 Results of Operations and Financial Condition | 2.02 On May 10, 2016, Zogenix, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2016. | a8-k3x31x16er.htm |
| 2016-05-05 | 8-K | 2016-05-05 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d180171d8k.htm |
| 2016-05-05 | 8-K | 2016-05-05 | 8.01 Other Events | 8.01 On May 5, 2016, Zogenix, Inc. (the “Company”) announced new data which continues to demonstrate the sustained effectiveness and cardiovascular safety of ZX008 (low-dose fenfluramine) as an adjunctive therapy for seizures associated with Dravet syndrome. | d356852d8k.htm |
| 2016-04-20 | 8-K | 2016-04-20 | 7.01 Regulation FD Disclosure | 7.01 Beginning on April 20, 2016 and continuing until April 22, 2016, representatives of Zogenix, Inc. will be attending meetings with investors, analysts and other parties. | d183795d8k.htm |
| 2016-03-10 | 8-K | 2016-03-10 | 2.02 Results of Operations and Financial Condition | 2.02 On March 10, 2016, Zogenix, Inc. issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2015. | a8-k12x31x15er.htm |
| 2016-01-19 | 8-K | 2016-01-19 | 8.01 Other Events | 8.01 January 19, 2016, Zogenix, Inc. (the “Company”) announced receipt of Fast Track designation from the U.S. Food and Drug Administration (the “FDA”) for the development program of its investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy. | d116317d8k.htm |
| 2016-01-11 | 8-K | 2016-01-11 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 8.01 Other Events | 2.02 On January 11, 2016, Zogenix, Inc. (the “Company” or “Zogenix”) announced that its preliminary unaudited cash and cash equivalents as of December 31, 2015 were approximately $155.9 million. 7.01 Beginning on January 11, 2016, representatives of Zogenix will be attending meetings with investors, analysts and other parties in connection with the J.P. Morgan 33rd Annual Healthcare Conference in San Francisco, California. 8.01 On January 11, 2016, Zogenix announced the initiation of the first Phase 3 clinical trial for its lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. | d105168d8k.htm |